ÌìÏÂÉúÃü¿ÆÑ§Ç°Ñض¯Ì¬Öܱ¨£¨°ËÊ®£©
£¨6.17-6.23/2012£©
Ò»¾º¼¼¹ú¼Ê¼¯ÍÅ:ÌÕ¹úÐÂ
¡¡¡¡Ö÷ÒªÄÚÈÝ£ºÏ¸°ûÖÜÆÚͬ²½ÕϰÓÚG1ÆÚÔö½ø°©Ï¸°û¶Ô¿¹°©Ò©ÎïµÄÃô¸ÐÐÔºÍϸ°ûµòÍö; ´óÄÔµÄÐÅÏ¢¸ßËÙ·; ·¢Ã÷Foxo3aÖú³¤°©Ö¢¸Ä±äÏÖÔÚµÄÖÎÁÆÄ£Ê½; »ùÖʸÕÐÔ¿ØÖÆÁËÄÚÆ¤·Ö½âºÍÐÄÔàǰÌåµÄÐÎ̬±¬·¢; ÓÃÓÚÉúÎ﹤³ÌÉöÔàµÄ¡°½ÅÊּܡ±; ÔöÇ¿Thbd-aPCͨ·µÄ×÷ÓÃÄܹ»»º½âµçÀë·øÉäËðÉË¡£
¡¡¡¡½¹µã¶¯Ì¬£ºÏ¸°ûÖÜÆÚͬ²½ÕϰÓÚG1ÆÚÔö½ø°©Ï¸°û¶Ô¿¹°©Ò©ÎïµÄÃô¸ÐÐÔºÍϸ°ûµòÍö¡£
1. ϸ°ûÖÜÆÚͬ²½ÕϰÓÚG1ÆÚÔö½ø°©Ï¸°û¶Ô¿¹°©Ò©ÎïµÄÃô¸ÐÐÔºÍϸ°ûµòÍö
¡¾¶¯Ì¬¡¿ÃÀ¹ú¿ÆÑ§¼Ò×î½ü·¢Ã÷ÁËÒ»ÖÖÌá¸ß¶à·¢ÐÔ¹ÇËèÁöÖÎÁÆÐ§ÂʵÄÕ½ÂÔ. ͨ¹ýÁ½ÖÖ¿¹°©Ò©Îï×¼È·ÕÆÎÕʱ»úµÄ˳ÐòʹÓÃ, ·ÖÁ½²½Ê¹°©Ï¸°ûÏÈÏ÷Èõ¶Ô¿¹Á¦¼Ì¶ø±»É±ËÀ. Ê×ÏÈÊÇÓÃÊÔÑéÒ©ÎïPD0332991,¼Ì¶øÊÇÒѱ»Åú×¼ÓÃÓÚ¹ÇËèÁöºÍÁܰÍÁöµÄÒ©ÎïÅðÌæ×ôÃ×(bortezomib),Ò»ÖÖÂѰ×øÒÖÖÆ¼Á, ÒÔµÍÓÚÕý³£µÄ¼ÁÁ¿£¬ÓÕµ¼´Óͬ²½µÄϸ°ûÖÜÆÚG1ÆÚ¸Õ¸ÕÊͷųöÀ´µÄ°©Ï¸°û×Ôɱ¡£»ù´¡ÉϽ²°©Ö¢ÊÇÒ»ÖÖϸ°ûÔöֳʧ¿ØµÄ¼²²¡£¬Ïà¶ÔµÄ£¬¿µ½¡¸öÌåÄÚϸ°ûÆÆËéÊÜϸ°ûÖÜÆÚµÄµ÷¿Ø£¬Ò»ÏµÁÐÓÐÐòµÄ³ÌÐòÐÔ»ùÒò±í´ï±¬·¢µÄ¸ß¶È¿ØÖƵÄÂѰ×ÍøÂçÇý¶¯Ï¸°ûͨ¹ý¸÷¸ö¼ì²éÕ¾¡£ ÒÀÀµÏ¸°ûÖÜÆÚÂѰ׵ļ¤Ã¸£¨CDKs£©Íƶ¯Ï¸°ûÂÄÀúÆäÖÜÆÚÐÔµÄËĸö½×¶Î¡£ÆäÖÐCDK4ºÍCDK6ÍÆ¶¯Ï¸°ûͨ¹ýG1ÆÚ½øÈëºóÃæ½×¶Î¾ÙÐÐϸ°ûÆÆË飬¶øPD0332991ÊÇÒ»¸ö¶ÔCDK4ºÍCDK6Óи߶ÈÑ¡ÔñÐÔµÄС·Ö×Ó£¬Äܹ»¿ÉÄæµÄÒÖÖÆÕâÁ½¸öø£¬Ò»Á¬Ê¹ÓÃPD0332991Äܹ»½«ËùÓа©Ï¸°ûͬ²½ÓÚG1ÆÚ£¬ÔÚG1ÆÚµÄºã¾ÃÕϰÈÅÂÒÁ˰©Ï¸°ûµÄ»ùÒò±í´ï£¬Ôö´óÁËÆä´úл¸ººÉºÍ¸´ÖÆDNAµÄÄÜÁ¿ÐèÇó£¬Ï÷Èõ²¢Ê¹°©Ï¸°û¶Ô¹Å°å¿¹°©Ò©Îï¸üΪÃô¸Ð£¬´ó´óÔöÌíÁËÅðÌæ×ôÃ×ÓÕµ¼µÄ°©Ï¸°û×Ôɱ¡£½øÒ»²½µÄÑо¿·¢Ã÷ÔÚPD0332991Ôì³ÉµÄG1ÆÚÕϰʱ´ú£¬¹ÇËèÁöϸ°ûʧȥÁ˱ØÐèµÄ´æ»îÒò×ÓIRF4ÂѰף¬µ«·ºÆðÁ˼¸ÖÖ´ÙµòÍöÂѰס£
¡¾µãÆÀ¡¿ ÕâЩ·¢Ã÷Ê×´ÎÅú×¢°©Ï¸°ûϸ°ûÖÜÆÚµ÷¿ØÒªº¦µÄ´æ»îºÍµòÍö»ùÒò£¬Ò²´ú±íÁËϸ°ûÖÜÆÚµÄÉúÎïѧ»ù´¡Ñо¿ÓëÖ±½ÓҽѧӦÓõÄÎÞ·ìÕûºÏ¡£¸ÃÖÎÁư©Ö¢µÄÕ½ÂÔÄÜ·ñÖÎÓú»ò´ó´ó¸ÄÉÆ¶à·¢ÐÔ¹ÇËèÁö»¹ÐèÆÚ´ýÈËÌåÁÙ´²ÊµÑéµÄЧ¹û¡£
¡¾²Î¿¼ÂÛÎÄ¡¿
Blood, 2012; DOI: 10.1182/blood-2012-03-415984
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4
X. Huang, M. Di Liberto, D. Jayabalan, et al.
Dysregulation of cyclin-dependent kinase (CDK)4 and CDK6 by gain of function or loss of inhibition is common in human cancer including multiple myeloma, but success in targeting CDK with broad-spectrum inhibitors has been modest. By selective and reversible inhibition of CDK4/CDK6, we have developed a strategy to both inhibit proliferation and enhance cytotoxic killing of cancer cells. We show that induction of prolonged early-G1 arrest (pG1) by CDK4/CDK6 inhibition halts gene expression in early-G1 and prevents expression of genes programmed for other cell cycle phases. Removal of the early-G1 block leads to S-phase synchronization (pG1-S) but fails to completely restore scheduled gene expression. Consequently, the IRF4 protein required to protect myeloma cells from apoptosis is markedly reduced in pG1 and further in pG1-S in response to cytotoxic agents such as the proteasome inhibitor bortezomib. The coordinated loss of IRF-4 and gain of Bim sensitize myeloma tumor cells to bortezomib-induced apoptosis in pG1 in the absence of Noxa and more profoundly in pG1-S in cooperation with Noxa in vitro. Induction of pG1 and pG1-S by reversible CDK4/CDK6 inhibition further augments tumor-specific bortezomib killing in myeloma xenografts. Reversible inhibition of CDK4/CDK6 in sequential combination therapy thus represents a novel mechanism-based cancer therapy.
2. ´óÄÔµÄÐÅÏ¢¸ßËÙ·
¡¾¶¯Ì¬¡¿ºÉÀ¼ºÍÃÀ¹ú¿ÆÑ§¼Ò¶ÔÈËÌå´óÄԽṹÉñ¾ÍøÂçÅþÁ¬µÄÑо¿×î½ü·¢Ã÷ÁËÒ»ÀàÌØÊâµÄ´óÄÔÇøÓò£¬ËüÃǸ߶Ȼ¥ÁªºÍ´¦ÓÚÖÐÐÄְ룬ÕâЩÊàÅ¦ÇøÓòÏ໥Ç×½üÅþÁ¬£¬ÔÚÈËÄÔÖÐÐγÉÒ»¸ö¡°¸»È˾ãÀÖ²¿¡±£¬ÅþÁ¬ÕâЩÊàÅ¦ÇøÓòµÄÄÇЩͨ·ÐγÉÁË´óÄÔͨѶµÄÒ»ÆäÖÐÐÄµÄ¸ßÆÆ·Ñ£¨ÄÜÁ¿ºÍ¿Õ¼äÉÏ£©¸ßÈÝÁ¿µÄÖ÷¸ÉÍø£¬Õ¼ÓÐÁË×ÜÌåÍ¨Ñ¶ÆÆ·ÑµÄ40%¡£²¢ÇÒ£¬Éñ¾½ÚµãÖ®¼ä69%µÄͨѶ×î¶Ìͨ·Ҫ;¾¡°¸»È˾ãÀÖ²¿¡±£¬´ó²¿·ÖÕâÀàͨѶ;¾¶Óɾ®È»ÓÐÐòµÄ·¶Î×é³É£¬ÏȽøÈëÔÙ´©Ô½£¬ºóÍÑÀë¡°¸»È˾ãÀÖ²¿¡±¡£ÕâÖÖÓÐÐòµÄ×î¶Ì;ͨѶÏß·µÄÆÕ±é±£´æÒâζ×ÅÖÐÊàͨѶʹÓòî±ðÄÔÇøÖ®¼äÐÅϢת´ïµÄ¶¯Ì¬Ïß·°²ÅÅ£¬ÆäÖи߶ÈÖÐÐÄְλµÄ¡°¸»È˾ãÀÖ²¿¡±ÆäÖ÷Òª×÷Óá£ÕâЩÑо¿Ð§¹ûÅú×¢¡°¸»È˾ãÀÖ²¿¡±µÄÖ÷¸ÉÍøÔÚ´óÄÔÇøÓò¼äÐźŽ»Í¨ÉÏÆðÖ÷Òª×÷Óã¬ÐγÉÁËÖÐÊàְλµÄ¸ßÆÆ·Ñ¸ßÈÝÁ¿µÄ´óÄÔͨѶÖ÷¸ÉÍø£¬ÔÚ¼¸Ê®ÒÚÄÔϸ°û¼äÌṩÁË¿ìËÙÓÐÓõÄͨѶ£¬ÎüÄÉ£¬×ª»»ºÍת´ïÐÅÏ¢¡£
¡¾µãÆÀ¡¿ ¸ÃÑо¿¹ØÓÚ´óÄÔÔõÑù¸ßЧ´¦Öóͷ£³ÁÖØµÄÐÅϢת´ïÓÐÁ˸üÉîÈëµÄÃ÷È·¡£
¡¾²Î¿¼ÂÛÎÄ¡¿
Proceedings of the National Academy of Sciences, 2012 DOI:10.1073/pnas.1203593109
High-cost, high-capacity backbone for global brain communication
Martijn P. van den Heuvel, Ren¨¦ S. Kahn, Joaqu¨ªn Goñi and Olaf Sporns.
Network studies of human brain structural connectivity have identified a specific set of brain regions that are both highly connected and highly central. Recent analyses have shown that these putative hub regions are mutually and densely interconnected, forming a ¡°rich club¡± within the human brain. Here we show that the set of pathways linking rich club regions forms a central high-cost, high-capacity backbone for global brain communication. Diffusion tensor imaging (DTI) data of two sets of 40 healthy subjects were used to map structural brain networks. The contributions to network cost and communication capacity of global cortico-cortical connections were assessed through measures of their topology and spatial embedding. Rich club connections were found to be more costly than predicted by their density alone and accounted for 40% of the total communication cost. Furthermore, 69% of all minimally short paths between node pairs were found to travel through the rich club and a large proportion of these communication paths consisted of ordered sequences of edges (¡°path motifs¡±) that first fed into, then traversed, and finally exited the rich club, while passing through nodes of increasing and then decreasing degree. The prevalence of short paths that follow such ordered degree sequences suggests that neural communication might take advantage of strategies for dynamic routing of information between brain regions, with an important role for a highly central rich club. Taken together, our results show that rich club connections make an important contribution to interregional signal traffic, forming a central high-cost, high-capacity backbone for global brain communication.
3. ·¢Ã÷Foxo3aÖú³¤°©Ö¢¸Ä±äÏÖÔÚµÄÖÎÁÆÄ£Ê½
¡¾¶¯Ì¬¡¿×î½üÃÀ¹ú¿ÆÑ§¼Ò·¢Ã÷Ò»ÖÖ±»ÆÕ±éÒÔΪ¿ÉÒÔ¶Ô¿¹¶àÖÖ°©Ö¢µÄ·Ö×ÓFoxo3a ÏÖʵÉÏ×ÊÖúÁËÖÂÃüµÄ¼××´ÏÙ°©Éú³¤£¬¶øÏÖÔÚÔÚÈËÌåÊÔÑéÖеݩ֢ÁÆ·¨¿ÉÄÜÖú³¤ÕâÒ»×÷Óá£ËûÃÇÔÚδ·Ö½âµÄ¼××´ÏÙ°©ÖвæÍ·×ªÂ¼Òò×ÓFoxo3a²»ÊÇÔÒÔΪµÄÖ×ÁöÒÖÖÆÒò×Ó£¬Ïà·´ÊÇÖÂÃüµÄÖ×ÁöÔö½øÒò×Ó¡£ÔÚÊÔÑéÊÒ´ËÖÖÖ×ÁöÄ£×ÓÖн«Foxo3a¹Ø±Õ£¬°©Ï¸°ûÉú³¤»ºÂý£¬µ«ÆÌ¿ªFoxo3aºó°©Ï¸°ûÉú³¤¾Í¿ìµÄ¶àÁË¡£ÒÔǰµÄÊìϤÊÇ£ºFoxo3aÓ¦¶ÔÖÖÖÖϸ°û°üÀ¨°©Ï¸°ûÖб¬·¢µÄѹÁ¦£¬·¿ªÏ¸°ûºËÀïµÄ´¥·¢Ï¸°ûéæÃüµÄ»ùÒò£¬¶ø°©Ï¸°ûͨ¹ýAktÂѰ׽«Foxo3a´Óϸ°ûºË×ªÒÆµ½Ï¸°ûÖÊÖÐÆÊÎöµô¶ø¹Ø±ÕÆä¹¦Ð§¡£¸ÃÑо¿Ê¹ÓÃAktÒÖÖÆ¼Á½«°©Ï¸°ûµÄFoxo3aÁôÔÚϸ°ûºËÀï, ±¾ÏëËü×ÊÖúɱËÀ°©Ï¸°û£¬È´ÊӲ쵽Ëü¼ÓËÙÁ˰©Ï¸°ûµÄÉú³¤¡£ÕâʹµÃÎÒÃÇÐèÒªÖØÐÂ˼Á¿AktÒÖÖÆ¼ÁÔÚ°©Ö¢ÖÎÁÆÖеÄʹÓã¬ÒòÆä»úÀíÖ®Ò»ÊÇʹFoxo3aÔÚϸ°ûºËÖмá³Ö»îÐÔ¡£¸ÃÑо¿»¹·¢Ã÷Foxo3a·¿ªÁËϸ°ûÖÜÆÚÂѰ×A1µÄ»ùÒò±í´ï£¬¶øÏ¸°ûÖÜÆÚÂѰ×A1ÊÇÔö½ø°©Ï¸°ûÉú³¤µÄ¡£
¡¾µãÆÀ¡¿ ¸ÃÑо¿·¢Ã÷ÁËFoxo3a¶Ô°©Ï¸°ûµÄÕý·´Ë«ÖØ×÷Ó㬿ÉÄܸıäÏÖÔÚ°©Ö¢ÖÎÁƵÄһЩ¼ÈÓÐģʽ¡£
¡¾²Î¿¼ÂÛÎÄ¡¿
Journal of Cell Science, June 20, 2012 DOI: 10.1242/jcs.097428
Foxo3a drives proliferation in anaplastic thyroid carcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies
Laura A. Marlow, Christina A. von Roemeling, Simon J. Cooper, et al.
The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth via transcriptional regulation of key genes regulating cell cycle arrest and apoptosis. In many types of cancer, in response to growth factor signaling, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Here we show that FoxO3a remains nuclear in anaplastic thyroid carcinoma (ATC). This correlates with lack of Akt phosphorylation at S473 in ATC cell lines and patient ATC tissues, providing a potential explanation for nuclear FoxO3a. Mechanistically, nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. Silencing FoxO3a with a reverse genetics approach leads to down-regulation of CCNA1 mRNA and protein. This combined data implicates an entirely novel function for FoxO3a in ATC promotion by enhancing cell cycle progression and tumor growth via transcriptional upregulation of cyclin A1. This is clinically relevant since we detected highly elevated CCNA1 mRNA and protein levels in ATC patient tumor tissues. Our data indicate therapeutic inactivation of FoxO3a may lead to attenuation of tumor expansion in ATC. This new paradigm also suggests caution related to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways.
4. »ùÖʸÕÐÔ¿ØÖÆÁËÄÚÆ¤·Ö½âºÍÐÄÔàǰÌåµÄÐÎ̬±¬·¢
¡¾¶¯Ì¬¡¿×éÖ¯·¢ÓýºÍÔÙÉúÇ£Éæµ½Ï¸ÃÜÐе÷½âºÏµÄ¶àÖÖÀú³Ì£º³£×¤¸Éϸ°ûºÍǰÌåϸ°ûµÄÑ¡ÔñÐÔÔöÖ³£¬·Ö½âΪĿµÄÌåϸ°û£¬¿Õ¼äÐÎ̬µÄ×éÖ¯¡£ÃÀ¹ú¿ÆÑ§¼Ò¶ÔÕâÒ»Àú³ÌÖлúеÇéÐεÄ×îÐÂÑо¿ÏÔʾԴ×ÔÍâµØÐÄÔà×éÖ¯µÄ¶àÄÜϸ°ûÒ»Á¬¼à²âϸ°û»ùÖʵĸնȲ¢ÏÔʾµ±¸Õ¶ÈºÜÊÇ¿¿½üÐļ¡Ï¸°ûʱ»áÔöÇ¿ÔöÖ³£¬ÄÚÆ¤·Ö½âºÍÐÎ̬±¬·¢¡£ÕâЩÀú³ÌµÄ»úеµ÷¿ØÐèÒªp190RhoGAP£¬Ò»ÖÖÕë¶ÔRhoAµÄÄñÜÕÈýÁ×Ëáø¼¤»îÂѰף¬Í¨¹ýÒÀÀµºÍ²»ÒÀÀµRhoAµÄ»úÖÆÆð×÷Óá£ÕâÒ»·¢Ã÷¿ÉÄÜÒý³ö¸üºÃµÄÖÎÁÆÐÄÔಡµÄÒªÁì¡£Ðļ¡×éÖ¯ÂÄÀúÐÄÔಡ±¬·¢ºóÒ»Ñùƽ³£»áÐγÉÐéÈõµÄ°ÌºÛ£¬¶ø×î½üÓÐһЩ±¨µÀ¿ÉÓøÉϸ°ûÉú²ú¿µ½¡×éÖ¯×èÖ¹°ÌºÛµÄ±¬·¢¡£
¡¾µãÆÀ¡¿ p190RhoGAPµÄ·¢Ã÷¼°Æä»úеµ÷¿Ø×÷ÓûáÓÐÖúÓÚ¸Éϸ°û˳ËìÄð³ÉÌØ¶¨¿µ½¡×éÖ¯¡£¸ÃÑо¿ÔöÇ¿ÁËÎÒÃǶԸÉϸ°ûÉúÎïѧµÄÃ÷È·²¢ÌáÐÑÁËз½·¨À´¿ØÖÆÐÉϸ°ûÔÚÒÆÖ²ÈëÐÄÔàǰºóµÄÐÐΪ¡£
¡¾²Î¿¼ÂÛÎÄ¡¿
Science Signaling, 2012; 5 (227): ra41 DOI: 10.1126/scisignal.2003002
Matrix Rigidity Controls Endothelial Differentiation and Morphogenesis of Cardiac Precursors
Kshitiz, M. E. Hubbi, E. H. Ahn, et al.
Tissue development and regeneration involve tightly coordinated and integrated processes: selective proliferation of resident stem and precursor cells, differentiation into target somatic cell type, and spatial morphological organization. The role of the mechanical environment in the coordination of these processes is poorly understood. We show that multipotent cells derived from native cardiac tissue continually monitored cell substratum rigidity and showed enhanced proliferation, endothelial differentiation, and morphogenesis when the cell substratum rigidity closely matched that of myocardium. Mechanoregulation of these diverse processes required p190RhoGAP, a guanosine triphosphatase¨Cactivating protein for RhoA, acting through RhoA-dependent and -independent mechanisms. Natural or induced decreases in the abundance of p190RhoGAP triggered a series of developmental events by coupling cell-cell and cell-substratum interactions to genetic circuits controlling differentiation.
5. ÓÃÓÚÉúÎ﹤³ÌÉöÔàµÄ¡°½ÅÊּܡ±
¡¾¶¯Ì¬¡¿ÃÀ¹ú¿ÆÑ§¼ÒÔÚʵÑéÊÒÖÐÖÆÔìÌæ»»ÉöÔàµÄºã¾ÃÏîÄ¿×î½üµÖ´ïÁËÒ»¸öÔçÆÚÀï³Ì±®£¬ËûÃÇÓÃÖíµÄÉöÔàÈ¥³ýËùÓж¯Îïϸ°û£¬Ö»ÁôÆ÷¹Ù¹Ç¼Ü£¬ÖÆÔì³öÁËÖ§³Ö½á¹¹¡°½ÅÊּܡ±£¬²¡ÈË×Ô¼ºµÄϸ°û¿ÉÒÔÔÚÉÏÃæÉú³¤ÐÎ³ÉµÄÆ÷¹ÙÀíÂÛÉϲ»»á±»²¡ÈË×ÔÉíËùÇãÔþ¡£ÔÙÉúҽѧÒѾÀֳɵØÖÆÔìÁËÉúÎ﹤³ÌƤ·ô£¬Èí¹Ç£¬°òë×£¬ÊäÄò¹Ü£¬Æø¹ÜºÍѪ¹ÜÖ²È뻼ÕßÌåÄÚ¡£ÕâЩ½á¹¹ÔÚ·¢Óý³ö×ÔÉíµÄѪ¹Ü֮ǰÄܹ»ÁÚ½üµÄѪ¹Ü×éÖ¯»ñÈ¡ÑõÆøºÍÑøÁÏ¡£¿ÉÊÇ£¬ÔÙÉúҽѧµÄ¡°Ê¥±¡±ÊÇÖÆÔì³ö¸üÖØ´óµÄÆ÷¹ÙÈçÉö£¬¸Î£¬ÐÄÔàºÍÒÈÏÙ¡£ÕâЩÆ÷¹Ùº¬Óдó×Úϸ°û±ØÐèÓÐ×Ô¼ºµÄÑõÆø¹©Ó¦²Å»ª´æ»î£¬ÕâÖÖÉúÎ﹤³Ì¾ÍÐèÒªÓÐÍêÕûÂö¹ÜϵͳµÄ¡°½ÅÊּܡ±¡£
¡¾µãÆÀ¡¿ ÕâÖÖÒìÖÖ½ÅÊּܲ¢²»¿ÉÍêȫɨ³ý»úÌåµÄÇãÔþ£¬²¢ÇÒÉúÎ﹤³ÌÖÆÔìÆ÷¹ÙÒ²²»ÊÇÔÙÉúҽѧµÄÊ¥±£¬ÕæÕýµÄÊ¥±ÊÇÎÞÐèÈκÎÒÆÖ²µÄÆ÷¹ÙÔλÔÙÉú¡£
¡¾²Î¿¼ÂÛÎÄ¡¿
Annals of Surgery, 2012; : 1 DOI:10.1097/SLA.0b013e31825a02ab
Production and Implantation of Renal Extracellular Matrix Scaffolds From Porcine Kidneys as a Platform for Renal Bioengineering Investigations
Giuseppe Orlando, Alan C. Farney, Samy S. Iskandar, et al.
BACKGROUND:
It is important to identify new sources of transplantable organs because of the critical shortage of donor organs. Tissue engineering holds the potential to address this issue through the implementation of decellularization-recellularization technology.
OBJECTIVE:
To produce and examine acellular renal extracellular matrix (ECM) scaffolds as a platform for kidney bioengineering.
METHODS:
Porcine kidneys were decellularized with distilled water and sodium dodecyl sulfate-based solution. After rinsing with buffer solution to remove the sodium dodecyl sulfate, the so-obtained renal ECM scaffolds were processed for vascular imaging, histology, and cell seeding to investigate the vascular patency, degree of decellularization, and scaffold biocompatibility in vitro. Four whole renal scaffolds were implanted in pigs to assess whether these constructs would sustain normal blood pressure and to determine their biocompatibility in vivo. Pigs were sacrificed after 2 weeks and the explanted scaffolds were processed for histology.
RESULTS:
Renal ECM scaffolds were successfully produced from porcine kidneys. Scaffolds retained their essential ECM architecture and an intact vascular tree and allowed cell growth. On implantation, unseeded scaffolds were easily reperfused, sustained blood pressure, and were tolerated throughout the study period. No blood extravasation occurred. Pathology of explantedscaffolds showed maintenance of renal ultrastructure. Presence of inflammatory cells in the pericapsular region and complete thrombosis of the vascular tree were evident.
CONCLUSIONS:
Our investigations show that pig kidneys can be successfully decellularized to produce renal ECM scaffolds. These scaffolds maintain their basic components, are biocompatible, and show intact, though thrombosed, vasculature.
6. ÔöÇ¿Thbd-aPCͨ·µÄ×÷ÓÃÄܹ»»º½âµçÀë·øÉäËðÉË
¡¾¶¯Ì¬¡¿ÃÀ¹úºÍµÂ¹ú¿ÆÑ§¼Ò×î½ü·¢Ã÷ÔöÇ¿ÀÏÊóÌåÄÚѪҺÖеÄÒ»ÖÖÂѰ×ͨ·Äܹ»±£»¤ÀÏÊóÃâÊÜ·øÉäΣÏÕ¡£ËûÃÇ·¢Ã÷ͨ¹ýÖØ×éµÄѪ˨µ÷ÀíÂѰ׻ò¼¤»îµÄÂѰ×CÔöÇ¿Thbd-aPC ͨ·µÄ×÷Óã¬Äܹ»»º½âµçÀë·øÉäÒýÆðµÄ×éÖ¯ËðÉ˺ÍÖÂÃüÐÔ¡£¸ÃÑо¿Õ¹ÏÖÁËǰËùδ֪µÄThbd-aPC ͨ·ÔÚ»º½â·øÉäΣÏÕ·½ÃæµÄ×÷Óá£Í¨³£¸Ãͨ·ÊÇÔ¤·ÀѪ˨Ðγɣ¬×ÊÖú»úÌå¶Ô¿¹Ñ¬È¾£¬¶ø¸ÃÑо¿·¢Ã÷Õâһͨ·×ÊÖú¹ÇËèѪϸ°û´Ó·øÉäËðÉËÖлָ´£¬µ«Æä±£»¤×÷ÓÃÖ»ÔÚ±»ÕÕÉäµÄÀÏÊóÄ£×ÓÌåÄÚ±¬·¢£¬ÌåÍâûÓÐ×÷Óã¬Òâζ×ÅËüÐèÒªÌåÄÚÆäËüϸ°û»òÎïÖʵÄ×ÊÖú¡£
¡¾µãÆÀ¡¿ ¸ÃÑо¿Ö¤Êµ¶¯ÎïÌåÄÚÓÐ×ÊÖú¶Ô¿¹µçÀë·øÉäµÄ»úÖÆ£¬Ò²ÓÐÒªÁìÈ¥ÔöÇ¿ÕâÒ»»úÖÆ¡£
¡¾²Î¿¼ÂÛÎÄ¡¿
Nature Medicine, 24 June 2012 DOI:10.1038/nm.2813
Pharmacological targeting of the thrombomodulin¨Cactivated protein C pathway mitigates radiation toxicity
Hartmut Geiger, Snehalata A Pawar, Edward J Kerschen, et al.
Tissue damage induced by ionizing radiation in the hematopoietic and gastrointestinal systems is the major cause of lethality in radiological emergency scenarios and underlies some deleterious side effects in patients undergoing radiation therapy. The identification of target-specific interventions that confer radiomitigating activity is an unmet challenge. Here we identify the thrombomodulin (Thbd)-activated protein C (aPC) pathway as a new mechanism for the mitigation of total body irradiation (TBI)-induced mortality. Although the effects of the endogenous Thbd-aPC pathway were largely confined to the local microenvironment of Thbd-expressing cells, systemic administration of soluble Thbd or aPC could reproduce and augment the radioprotective effect of the endogenous Thbd-aPC pathway. Therapeutic administration of recombinant, soluble Thbd or aPC to lethally irradiated wild-type mice resulted in an accelerated recovery of hematopoietic progenitor activity in bone marrow and a mitigation of lethal TBI. Starting infusion of aPC as late as 24 h after exposure to radiation was sufficient to mitigate radiation-induced mortality in these mice. These findings suggest that pharmacologic augmentation of the activity of the Thbd-aPC pathway by recombinant Thbd or aPC might offer a rational approach to the mitigation of tissue injury and lethality caused by ionizing radiation.